Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Stock: Can It Change The Game?

In the last trading session, 6.81 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) were traded, and its beta was 0.76. Most recently the company’s share price was $8.77, and it changed around -$0.6 or -6.40% from the last close, which brings the market valuation of the company to $1.89B. RXRX currently trades at a discount to its 52-week high of $16.75, offering almost -90.99% off that amount. The share price’s 52-week low was $4.54, which indicates that the current value has risen by an impressive 48.23% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 5.54 million shares, with the 3-month average coming to 7.17 million.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information

Instantly RXRX has showed a red trend with a performance of -6.40% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -11.05% year-to-date, but still down -16.71% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -31.54% down in the 30-day period. We can see from the shorts that 43.52 million shares have been sold at a short interest cover period of 4.45 day(s).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts

Recursion Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 14.64 percent over the past six months and at a -3.16% annual growth rate that is well below the industry average of 8.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -23.50% in revenue this quarter, and will report a decrease of -10.50% in the next quarter. The year-over-year growth rate is expected to be 26.00%, up from the previous year.

Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $12.65 million in revenue for the current quarter. 6 analysts expect Recursion Pharmaceuticals Inc to make $13.17 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $12.13 million and $11.02 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 4.30%. Forecasts for the next quarter put sales growth at 19.50%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.41%. Recursion Pharmaceuticals Inc earnings are expected to increase by -9.14% in 2024, but the outlook is positive 12.00% per year for the next five years.

RXRX Dividends

Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released around May 06 and May 10.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 5.77% of Recursion Pharmaceuticals Inc shares, and 92.41% of them are in the hands of institutional investors. The stock currently has a share float of 98.06%. Recursion Pharmaceuticals Inc stock is held by 283 institutions, with Baillie Gifford and Company being the largest institutional investor. By Jun 29, 2023, it held 12.30% of the shares, which is about 25.1 million shares worth $187.48 million.

Blackrock Inc., with 5.69% or 11.62 million shares worth $86.8 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard U.S. Growth Fund were the top two Mutual Funds as of Sep 29, 2023. The former held 6.8 million shares worth $52.0 million, making up 3.33% of all outstanding shares. On the other hand, Vanguard U.S. Growth Fund held roughly 3.97 million shares worth around $34.85 million, which represents about 1.95% of the total shares outstanding.